[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100538677":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":24,"studyPopulation":17,"armGroups":25,"interventions":32,"overallOfficials":36,"centralContacts":41,"locations":51,"responsibleParty":67,"collaborators":17,"id":71,"slug":17,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":17,"eligibilityCriteria":75,"healthyVolunteers":72,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":17,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":53,"whyStopped":17,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"University of Jordan","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"safety profile lab tests","-patients will be monitored for any possible adverse events resulting from the injection of MSCs.","follow-up duration is 12 months",[14],{"measure":15,"description":16,"timeFrame":12},"efficacy change in Adult ADHD Self-Report Scale (ASRS)","-The subjects will be monitored with ASRS at baseline, 3, 6, 9, and 12 months",null,{"allocation":19,"interventionModel":20,"interventionModelDescription":17,"primaryPurpose":21,"observationalModel":17,"timePerspective":17,"maskingInfo":22},"NA","SINGLE_GROUP","TREATMENT",{"masking":23,"maskingDescription":17,"whoMasked":17},"NONE","Autism spectrum disorders (ASDs) are characterized by core domains: persistent deficits in social communication and interaction; restricted, repetitive patterns of behavior, interests, or activities. ASDs comprise heterogeneous and complex neuro-developmental pathologies with well-defined inflammatory conditions and immune system dysfunction. Due to neurobiological changes underlying ASD development, cell-based therapies have been proposed and applied to ASDs. Indeed, stem cells show specific immunologic properties, which make them promising candidates for ASD treatment.",[26],{"label":27,"type":28,"description":29,"interventionNames":30},"WJMSC","EXPERIMENTAL","\\- Patients receive three intravenous doses of MSCs (1 million\u002Fkg) every two weeks as treatment.",[31],"Biological: WJMSC",[33],{"type":34,"name":27,"description":29,"armGroupLabels":35,"otherNames":17},"BIOLOGICAL",[27],[37],{"name":38,"affiliation":39,"role":40},"Abdallah Awidi, MD","Cell Therapy Center","STUDY_DIRECTOR",[42,47],{"name":43,"role":44,"phone":45,"phoneExt":17,"email":46},"Hanan Jafar, PhD","CONTACT","00962798871087","hanan.jafar@gmail.com",{"name":38,"role":44,"phone":48,"phoneExt":49,"email":50},"0096265355000","23960","abdalla.awidi@gmail.com",[52],{"facility":39,"status":53,"city":54,"state":17,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"RECRUITING","Amman","00962","Jordan","JO",{"type":59,"coordinates":60},"Point",[61,62],35.94503,31.95522,{"lat":62,"lon":61},[65,66],{"name":43,"role":44,"phone":45,"phoneExt":17,"email":46},{"name":38,"role":44,"phone":48,"phoneExt":49,"email":50},{"type":68,"investigatorFullName":69,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"PRINCIPAL_INVESTIGATOR","Hanan Jafar","Principal investigator","100538677",false,"NCT06293950","Allogeneic Wharton Jelly Mesenchymal Stromal Cell (WJMSC) for Treatment of Autism","Inclusion Criteria:\n\n* 14 subjects, 4-14 years of age, will be enrolled into this study, who meet the criteria for (ASD\n\nExclusion Criteria:\n\n* Age \\> 14 years.\n* Patient weighing \\\u003C 10 kg.\n* History of severe Allergy\n* History of severe head trauma, defined by loss of consciousness or hospitalization, skull fracture, or stroke.\n* Seizure within the last year before enrollment, or the need for seizure medications either at present or in the past.\n* Evidence or history of severe, moderate, or uncontrolled systemic disease.\n* Inability to follow the prescribed dosing and follow-up schedule.\n* Use of any stimulant or non-stimulant medication or medications given for attention deficit hyperactivity disorder (ADHD) must be discontinued 7 days before the initial randomized study period.\n* Subjects taking a selective serotonin reuptake inhibitor (SSRI) must be on a stable dose for a minimum of 30 days before entering the study.\n* History of premature birth \\\u003C35 weeks' gestation.\n* Prior history of stroke in utero or other in utero insult.","ALL","4 Years","14 Years",{"count":80,"type":81},14,"ESTIMATED","INTERVENTIONAL",[84],"PHASE1","Autism spectrum disorders (ASDs) are characterized by core domains: persistent deficits in social communication and interaction; restricted, repetitive patterns of behavior, interests, or activities.",[87],"Autism",[89,27],"autism","2025-01-23",{"date":92,"type":93},"2025-01-24","ACTUAL",{"date":95,"type":93},"2022-03-09",{"date":97,"type":81},"2027-12",{"name":5,"class":6},1]